Ultralife (ULBI) Q4 2025 earnings review
Core Operations Accelerate, but a $12.2M Write-off Crushes GAAP Earnings
Ultralife finished 2025 with a highly polarized quarter. Top-line metrics are accelerating: Revenue grew 10.6% YoY to $48.5M, and order backlog surged 22% sequentially to a record $110.2M. Furthermore, gross margin stabilized at 24.9% and Adjusted EBITDA spiked 46% YoY to $5.7M, showing that underlying manufacturing efficiencies are taking hold. However, GAAP Net Income reversed sharply into the red (-$7.4M) due to a massive $12.2M non-cash impairment charge as the company abruptly killed five legacy sub-brands. While the core Battery & Energy business is thriving on surging medical demand, the Communications Systems segment remains a severe laggard.
🐂 Bull Case
The 22% sequential surge in backlog to $110.2M provides massive revenue visibility heading into 2026, strongly suggesting that order push-outs from earlier in the year are finally converting.
After struggling with order timing and tough comps in earlier quarters (down 39% in Q2 and 12% in Q3), Medical battery organic sales skyrocketed 39.6% YoY in Q4.
🐻 Bear Case
The Communications Systems segment is deteriorating rapidly, with Q4 revenue down 35.2% YoY to just $2.6M, accompanied by a gross margin collapse to 19.9%.
The $12.2M trademark impairment effectively admits that prior acquisitions (like Accutronics and SWE) held inflated intangible value, destroying significant shareholder equity on paper.
⚖️ Verdict: ⚪
Neutral leaning Bullish. If investors can look past the ugly GAAP net loss caused by the one-time rebranding charge, the underlying cash generation (Adjusted EBITDA) and forward-looking demand (Backlog) are undeniably strong.
Key Themes
Backlog Reversing to Record Highs
After a steady deceleration in backlog throughout 2025 ($102.2M exiting 2024 to $89M in Q2), high-confidence orders are reversing back into intense growth. Exiting Q4, the backlog hit $110.2M (+22% QoQ). Management explicitly attributes this to 'strong order flow' and positions it as the foundation for 2026 growth.
Medical and Industrial Demand Accelerating
Organic growth in the Battery & Energy segment jumped 9.5% YoY, completely driven by commercial markets. Medical sales surged 39.6% (reversing sharp declines in Q2/Q3), and Industrial sales grew 20.4%. This validates management's prior claims that mid-year medical weakness was purely due to order timing, not lost market share.
Massive Intangible Asset Write-Off
Management abruptly retired five sub-brands (Accutronics, Southwest Electronic Energy, Excell Battery, McDowell Research, and AMTI) to unify under the Ultralife master brand. This triggered a non-cash intangible asset impairment of $12.2M. While strategically logical to reduce marketing redundancy, this massive write-down signals that the company historically overpaid for the brand equity of these acquisitions.
Communications Systems Segment Decelerating Severely
This segment is bleeding. Sales fell 35.2% YoY to $2.6M. Worse, the loss of volume caused gross margins to compress radically from 31.9% last year to 19.9% today. Despite management consistently citing 'timing of expected orders' as the excuse, this marks the fourth consecutive quarter of heavy, double-digit YoY contraction.
Macro: Oil & Gas Cycle Weakness
Oil & Gas market sales fell 3.6% organically in Q4. This continues a trend of deceleration driven by macroeconomic and geopolitical factors that have caused customers to delay capital projects. Until commodity prices stabilize higher, this high-margin vertical will remain a drag on the broader Battery & Energy segment.
Innovation: Realignment of Thionyl Chloride Operations
Management executed a targeted restructuring to consolidate four separate thionyl chloride/oil & gas manufacturing operations into a single unit. This moves the business away from siloed production toward a unified structure that will accelerate the ramp-up of new pipeline technologies like ThinCell and BA-53 batteries into high-volume production.
Debt Load Weighs on Cash Flow
The company's aggressive M&A strategy (Electrochem) has fundamentally altered its interest burden. While operating results improved, Q4 'Other Expense' included significant interest, leading to a full-year net interest expense of nearly $4.0M, up from $1.9M in FY24. Debt reduction must be a strict priority in 2026.
Other KPIs
Reversing. After bottoming out at 4.7% in Q3 due to supply chain inefficiencies, Adjusted EBITDA margin violently rebounded to 11.7% in Q4, generating $5.7M. This proves that management's recent lean manufacturing initiatives and facility closures (e.g., Calgary) are successfully stripping out structural costs.
Accelerating. Improved sequentially from 22.2% in Q3 and YoY from 24.2%. The Battery & Energy segment led the charge at 25.1%, absorbing factory costs far better than earlier in the year despite the continued weakness in the higher-margin Communications segment.
A severe anomaly. Spiked from $9.1M a year ago due entirely to the $12.2M trademark impairment and $1.1M in transition/litigation costs. Excluding the impairment charge, OpEx was 21.6% of revenue, slightly up from 20.8% a year earlier, reflecting the absorption of Electrochem overhead.
Guidance
Management did not provide hard numerical guidance for Revenue or EPS for FY26. However, they explicitly stated expectations to 'deliver sustainable profitable growth and incremental cash flow in 2026' to facilitate debt reduction and strategic CapEx. The 22% spike in backlog to $110.2M heavily supports this qualitative optimism.
Key Questions
Communications Systems Floor
With the Communications Systems segment shrinking by 35% YoY and margins collapsing below 20%, when do you expect this business to find a bottom, and are the delayed orders from 2025 definitively scheduled for 2026 delivery?
Margin Profile of the Backlog
The backlog surged 22% to $110M. Given the recent historical volatility in gross margins caused by tariffs and supply chain issues, what is the embedded margin profile of this newly acquired backlog compared to the 24.9% achieved in Q4?
Capital Allocation and Debt Amortization
You highlighted incremental cash flow in 2026 for debt reduction. What is your specific target for debt paydown in FY26, and how much of your operating cash flow is currently consumed by the higher interest expense from the Electrochem acquisition?